High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas

H. Deshmukh, T. H. Yeh, J. J. Yu, M. K. Sharma, Arie Perry, J. R. Leonard, M. A. Watson, David H. Gutmann, R. Nagarajan

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Pilocytic astrocytomas (PAs, WHO grade I) are the most common brain tumors in the pediatric and adolescent population, accounting for approximately one-fifth of central nervous system tumors. Because few consistent molecular alterations have been identified in PAs compared to higher grade gliomas, we performed array comparative genomic hybridization using two independent commercial array platforms. Although whole chromosomal gains and losses were not observed, a 1-Mb amplified region of 7q34 was detected in multiple patient samples using both array platforms. Copy-number gain was confirmed in an independent tumor sample set by quantitative PCR, and this amplification was correlated to both increased mRNA and protein expression of HIPK2, a homeobox-interacting protein kinase associated with malignancy, contained within this locus. Furthermore, overexpression of wild-type HIPK2, but not a kinase-inactive mutant, in a glioma cell line conferred a growth advantage in vitro. Collectively, these results illustrate the power and necessity of implementing high-resolution, multiple-platform genomic analyses to discover small and subtle, but functionally significant, genomic alterations associated with low-grade tumor formation and growth.

Original languageEnglish
Pages (from-to)4745-4751
Number of pages7
JournalOncogene
Volume27
Issue number34
DOIs
Publication statusPublished - Aug 7 2008
Externally publishedYes

Fingerprint

Astrocytoma
Glioma
Homeodomain Proteins
Central Nervous System Neoplasms
Neoplasms
Comparative Genomic Hybridization
Growth
Brain Neoplasms
Protein Kinases
Phosphotransferases
Pediatrics
Cell Line
Polymerase Chain Reaction
Messenger RNA
Population
Proteins

Keywords

  • aCGH
  • HIPK2 amplification
  • Pilocytic astrocytomas

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. / Deshmukh, H.; Yeh, T. H.; Yu, J. J.; Sharma, M. K.; Perry, Arie; Leonard, J. R.; Watson, M. A.; Gutmann, David H.; Nagarajan, R.

In: Oncogene, Vol. 27, No. 34, 07.08.2008, p. 4745-4751.

Research output: Contribution to journalArticle

Deshmukh, H, Yeh, TH, Yu, JJ, Sharma, MK, Perry, A, Leonard, JR, Watson, MA, Gutmann, DH & Nagarajan, R 2008, 'High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas', Oncogene, vol. 27, no. 34, pp. 4745-4751. https://doi.org/10.1038/onc.2008.110
Deshmukh, H. ; Yeh, T. H. ; Yu, J. J. ; Sharma, M. K. ; Perry, Arie ; Leonard, J. R. ; Watson, M. A. ; Gutmann, David H. ; Nagarajan, R. / High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. In: Oncogene. 2008 ; Vol. 27, No. 34. pp. 4745-4751.
@article{e6db66e73c884030b5f2bd68cf85ad72,
title = "High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas",
abstract = "Pilocytic astrocytomas (PAs, WHO grade I) are the most common brain tumors in the pediatric and adolescent population, accounting for approximately one-fifth of central nervous system tumors. Because few consistent molecular alterations have been identified in PAs compared to higher grade gliomas, we performed array comparative genomic hybridization using two independent commercial array platforms. Although whole chromosomal gains and losses were not observed, a 1-Mb amplified region of 7q34 was detected in multiple patient samples using both array platforms. Copy-number gain was confirmed in an independent tumor sample set by quantitative PCR, and this amplification was correlated to both increased mRNA and protein expression of HIPK2, a homeobox-interacting protein kinase associated with malignancy, contained within this locus. Furthermore, overexpression of wild-type HIPK2, but not a kinase-inactive mutant, in a glioma cell line conferred a growth advantage in vitro. Collectively, these results illustrate the power and necessity of implementing high-resolution, multiple-platform genomic analyses to discover small and subtle, but functionally significant, genomic alterations associated with low-grade tumor formation and growth.",
keywords = "aCGH, HIPK2 amplification, Pilocytic astrocytomas",
author = "H. Deshmukh and Yeh, {T. H.} and Yu, {J. J.} and Sharma, {M. K.} and Arie Perry and Leonard, {J. R.} and Watson, {M. A.} and Gutmann, {David H.} and R. Nagarajan",
year = "2008",
month = "8",
day = "7",
doi = "10.1038/onc.2008.110",
language = "English",
volume = "27",
pages = "4745--4751",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "34",

}

TY - JOUR

T1 - High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas

AU - Deshmukh, H.

AU - Yeh, T. H.

AU - Yu, J. J.

AU - Sharma, M. K.

AU - Perry, Arie

AU - Leonard, J. R.

AU - Watson, M. A.

AU - Gutmann, David H.

AU - Nagarajan, R.

PY - 2008/8/7

Y1 - 2008/8/7

N2 - Pilocytic astrocytomas (PAs, WHO grade I) are the most common brain tumors in the pediatric and adolescent population, accounting for approximately one-fifth of central nervous system tumors. Because few consistent molecular alterations have been identified in PAs compared to higher grade gliomas, we performed array comparative genomic hybridization using two independent commercial array platforms. Although whole chromosomal gains and losses were not observed, a 1-Mb amplified region of 7q34 was detected in multiple patient samples using both array platforms. Copy-number gain was confirmed in an independent tumor sample set by quantitative PCR, and this amplification was correlated to both increased mRNA and protein expression of HIPK2, a homeobox-interacting protein kinase associated with malignancy, contained within this locus. Furthermore, overexpression of wild-type HIPK2, but not a kinase-inactive mutant, in a glioma cell line conferred a growth advantage in vitro. Collectively, these results illustrate the power and necessity of implementing high-resolution, multiple-platform genomic analyses to discover small and subtle, but functionally significant, genomic alterations associated with low-grade tumor formation and growth.

AB - Pilocytic astrocytomas (PAs, WHO grade I) are the most common brain tumors in the pediatric and adolescent population, accounting for approximately one-fifth of central nervous system tumors. Because few consistent molecular alterations have been identified in PAs compared to higher grade gliomas, we performed array comparative genomic hybridization using two independent commercial array platforms. Although whole chromosomal gains and losses were not observed, a 1-Mb amplified region of 7q34 was detected in multiple patient samples using both array platforms. Copy-number gain was confirmed in an independent tumor sample set by quantitative PCR, and this amplification was correlated to both increased mRNA and protein expression of HIPK2, a homeobox-interacting protein kinase associated with malignancy, contained within this locus. Furthermore, overexpression of wild-type HIPK2, but not a kinase-inactive mutant, in a glioma cell line conferred a growth advantage in vitro. Collectively, these results illustrate the power and necessity of implementing high-resolution, multiple-platform genomic analyses to discover small and subtle, but functionally significant, genomic alterations associated with low-grade tumor formation and growth.

KW - aCGH

KW - HIPK2 amplification

KW - Pilocytic astrocytomas

UR - http://www.scopus.com/inward/record.url?scp=49149087048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149087048&partnerID=8YFLogxK

U2 - 10.1038/onc.2008.110

DO - 10.1038/onc.2008.110

M3 - Article

VL - 27

SP - 4745

EP - 4751

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 34

ER -